Neuros Medical, a California-based medical device company focused on alleviating chronic post-amputation pain, received $25 million in growth capital from Trinity Capital.
Neuros Medical’s Altius System incorporates the company’s patented platform technology, On-Demand Bioelectric Nerve Block, which patients initiate as needed for targeted pain relief. The technology blocks sensory nerves and has the potential to alleviate pain for many living with phantom limb and residual limb pain.
The growth capital will enable Neuros Medical to augment the recent equity raised and further scale operations to assist with their commercial launch.
“We appreciate the conviction Trinity has in the Neuros mission and our ability to scale commercialization, delivering this life-changing therapy to a large, underserved amputee population in desperate need of pain relief,” said David Veino, newly appointed president and CEO of Neuros Medical.
